CD274 and neoplasm: The introduction of ICIs, particularly consolidation therapy with PD-1/PD-L1 inhibitors after CCRT, has revolutionized outcomes, with phase III trials such as PACIFIC confirming prolonged survival and durable tumor control (Spigel et al., 2022; Faivre-Finn et al., 2021).